<DOC>
	<DOCNO>NCT00297856</DOCNO>
	<brief_summary>Pre-licensure study GSK Biologicals ' Boostrix® show generally safe well-tolerated . This post-licensure study design evaluate relatively uncommon/rare outcome large population cohort . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Post-marketing Safety Study GSK Biologicals ' Boostrix® Vaccine</brief_title>
	<detailed_description>Data collection utilization automate database study site . The collaborator Kaiser Permanente Vaccine Study Center .</detailed_description>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects age 10 18 year ( inclusive ) receive dose Boostrix safety followup information available</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Boostrix</keyword>
</DOC>